Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis-Reference-Cited by-同舟云学术

Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis

Published:2023-11-30 Issue:11 Volume:2023 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Tramacere Irene¹,Virgili Gianni²³,Perduca Vittorio⁴⁵,Lucenteforte Ersilia⁶,Benedetti Maria Donata⁷,Capobussi Matteo⁸,Castellini Greta⁸⁹,Frau Serena¹⁰,Gonzalez-Lorenzo Marien⁸¹¹,Featherstone Robin¹²,Filippini Graziella¹³

Affiliation:

1. Department of Research and Clinical Development, Scientific Directorate; Fondazione IRCCS Istituto Neurologico Carlo Besta; Milan Italy

2. Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA); University of Florence; Florence Italy

3. Ophthalmology; IRCCS – Fondazione Bietti; Rome Italy

4. Université Paris Cité, CNRS; MAP5; F-75006 Paris France

5. Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy; CESP; 94805, Villejuif France

6. Department of Statistics, Computer Science and Applications "G. Parenti"; University of Florence; Florence Italy

7. UOC Neurologia B - Policlinico Borgo Roma; Azienda Ospedaliera Universitaria Integrata; Verona Italy

8. Department of Biomedical Sciences for Health; University of Milan; Milan Italy

9. Unit of Clinical Epidemiology; IRCCS Galeazzi Orthopaedic Institute; Milan Italy

10. Brighton and Hove UK

11. Department of Oncology, Laboratory of Clinical Research Methodology; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Milan Italy

12. Evidence Production and Methods Directorate; Cochrane; Edmonton Canada

13. Scientific Director’s Office; Carlo Besta Foundation and Neurological Institute; Milan Italy

Publisher

Wiley

Subject

Pharmacology (medical)

Reference428 articles.

1. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses;Achiron;Neurology,1998

2. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiplesclerosis: a randomized, double-blind, placebo-controlled trial;Achiron;Archives of Neurology,2004

3. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study;Calabresi;The Lancet Neurology,2014

4. Efficacy and safety study of Peginterferon beta-1a in participants with relapsing multiple sclerosis (ADVANCE) clinicaltrials.gov/show/NCT00906399

5. Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis;Newsome;Multiple Sclerosis and Related Disorders,2015